Semaglutide
The drug that made the category, and is now trying to hold its lane.
Semaglutide has a decade of published evidence and is still the most-prescribed agent in the class. The desk follows the long-term data, the cardiovascular story, the oral formulation, and the real-world experience of patients who are now years in.
This Week's Feature
Hand-picked by the desk.
What the STEP Trials Showed About Semaglutide and Weight Loss
A plain-language look at what the STEP trials — and the SELECT heart study — actually found about semaglutide (Wegovy) for weight loss: how much people lost, what happens when they stop, and where the evidence stops short.
Read the feature →